Replimune Groupincis A Biotechnology Company Based In Woburnmassachusettswith Operations In Oxfordshireukfounded In 2015Replimune Specializes In Developing Oncolytic Immune Gene Therapies Aimed At Activating Systemic Anti Tumor Immune Responses For Cancer Treatmentthe Company Utilizes A Proprietary Platform To Engineer Viruses That Selectively Replicate In Tumors While Stimulating The Immune System Replimune S Product Pipeline Includes Oncolytic Viruses Enhanced With Immune Activating Transgeneskey Candidates Include Rp1Which Combines An Hsv 1 Backbone With Immune Activating Genesand Rp2 Rp3Designed To Amplify Immune Responses Furtherthe Company Focuses On Treating Solid Tumorsincluding Skinlungand Gastrointestinal Cancersand Collaborates With Academic Institutions And Industry Partners To Advance Its Clinical Developmentreplimune Has Raised Over $200 Million In Fundingincluding A $145 Million Ipo In 2018And Emphasizes Combination Therapies To Enhance Treatment Efficacy
